Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Infant Bacterial Therapeutics ABCHIX:IBTBS 27 Equity-to-Asset is 0.44 as of Jun. 2026, which is 54% below its 10-year median of 0.95. GuruFocus rates CHIX:IBTBS with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Infant Bacterial Therapeutics AB ranks worse than 71.35% on this metric.
The historical rank and industry rank for Infant Bacterial Therapeutics AB's Equity-to-Asset or its related term are showing as below:
CHIX:IBTBs'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44 Med: 0.95 Max: 0.99
Current: 0.44
During the past 12 years, the highest Equity to Asset Ratio of Infant Bacterial Therapeutics AB was 0.99. The lowest was 0.44. And the median was 0.95.
CHIX:IBTBs's Equity-to-Asset is ranked worse than 71.35% of 1410
companies
in the Biotechnology industry
Industry Median: 0.69
vs CHIX:IBTBs: 0.44
Infant Bacterial Therapeutics AB (CHIX:IBTBs) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Infant Bacterial Therapeutics AB Equity-to-Asset Related Terms
Infant Bacterial Therapeutics AB Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infant Bacterial Therapeutics AB Equity-to-Asset Chart
CHIX:IBTBS vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's Equity-to-Asset falls into.
Infant Bacterial Therapeutics AB Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infant Bacterial Therapeutics AB (CHIX:IBTBS) has a Equity-to-Asset of 0.44 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Infant Bacterial Therapeutics AB and its competitors. This is 54% below median its historical median of 0.95. Over the past decade, Infant Bacterial Therapeutics AB's Equity-to-Asset has ranged from 0.44 to 0.99. According to the industry distribution chart, Infant Bacterial Therapeutics AB ranks #1006 out of 1410 companies in the Biotechnology industry, placing it in the top 71.3%.
Is Infant Bacterial Therapeutics AB's Equity-to-Asset too high?
Infant Bacterial Therapeutics AB's current Equity-to-Asset of 0.44 is 54% below median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 0.99. The Biotechnology industry median Equity-to-Asset is 0.69. Infant Bacterial Therapeutics AB's value of 0.44 is 36.2% below this industry median. Based on the distribution chart, Infant Bacterial Therapeutics AB ranks #1006 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Infant Bacterial Therapeutics AB ranks #1006 out of 1410 companies for Equity-to-Asset. This places Infant Bacterial Therapeutics AB in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Infant Bacterial Therapeutics AB's value of 0.44 is 36.2% below this benchmark. Historically, Infant Bacterial Therapeutics AB's own Equity-to-Asset has ranged from 0.44 to 0.99 over the past decade. While the company's 10-year median is 0.95 vs. the industry median of 0.69, Infant Bacterial Therapeutics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infant Bacterial Therapeutics AB's current Equity-to-Asset of 0.44 is 36.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Infant Bacterial Therapeutics AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infant Bacterial Therapeutics AB's current Equity-to-Asset is 0.44, which is 54% below median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (CHIX:IBTBS) has a current Equity-to-Asset of 0.44. The current Equity-to-Asset is 0.44, which is 54% below median its 10-year median of 0.95 and 36.2% below the Biotechnology industry median of 0.69. Infant Bacterial Therapeutics AB's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (CHIX:IBTBS), the current Equity-to-Asset is 0.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infant Bacterial Therapeutics AB is a Swedish pharmaceutical company focused on developing drugs for diseases affecting premature infants. Its lead drug candidate is IBP-9414, based on the Lactobacillus reuteri bacterial strain found naturally in human breast milk, being developed to reduce the incidence of necrotizing enterocolitis and improve gastrointestinal function in premature babies. The company's pipeline also includes earlier-stage candidates such as IBP-1016 for gastroschisis, a rare and life-threatening condition in which infants are born with externalized gastrointestinal organs, along with IBP-1118 and IBP-1122. As a clinical-stage development company, it does not yet generate product revenue; its operations are funded through equity financing and it works toward regulatory approval and eventual commercialization of its drug candidates, primarily targeting the neonatal intensive care market in Europe and the United States.
27GF Score
Get the complete analysis for CHIX:IBTBS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:IBTBS has been successfully added to your 
